10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q1 2018

Filing Information

Form Type	10-Q
Accession Number	`0001193125-18-150803`
Period End Date	20180331
Filing Date	20180503
Fiscal Year	2018
Fiscal Period	Q1
XBRL Instance	teva-20180331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 89 Income Statement 47 Cash Flow Statement 59 Comprehensive Income 17

Balance Sheet 89 line items

Line Item	Tag	Value	Unit	Period
Preferred stock par or stated value per share	`PreferredStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Preferred stock par or stated value per share	`PreferredStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$900.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.42B	USD	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	3.70M	shares	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	3.70M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$6.29B	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.13B	USD	Point-in-time
Inventories	`InventoryNet`	$5.11B	USD	Point-in-time
Inventories	`InventoryNet`	$4.92B	USD	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.12B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.12B	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.10B	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.14B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$712.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$701.00M	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	107.00M	shares	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$17.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$566.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$14.69B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.38B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$574.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$463.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$832.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$932.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$7.67B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$7.42B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$17.31B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$17.64B	USD	Point-in-time
Goodwill	`Goodwill`	$28.46B	USD	Point-in-time
Goodwill	`Goodwill`	$28.41B	USD	Point-in-time
Total assets	`Assets`	$69.18B	USD	Point-in-time
Total assets	`Assets`	$70.61B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.30B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.65B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$7.41B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$7.88B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.07B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.93B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$607.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$549.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.63B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$3.01B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$876.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$724.00M	USD	Point-in-time
Liabilities held for sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$38.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.92B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.76B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$3.00B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$3.28B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.84B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.88B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$28.83B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$29.45B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$33.95B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$34.32B	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$51.87B	USD	Point-in-time
Total liabilities	`Liabilities`	$49.08B	USD	Point-in-time
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; March 31, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares	`PreferredStockValue`	$3.63B	USD	Point-in-time
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; March 31, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares	`PreferredStockValue`	$3.70B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,124 million shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; March 31, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,124 million shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.48B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.44B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$-3.81B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$-2.69B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.85B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.74B	USD	Point-in-time
Treasury shares as of March 31, 2018 and December 31, 2017 -106 million ordinary shares and 107 million ordinary shares, respectively	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Treasury shares as of March 31, 2018 and December 31, 2017 -106 million ordinary shares and 107 million ordinary shares, respectively	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$18.62B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$17.36B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.39B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.48B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$20.10B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$70.61B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$69.18B	USD	Point-in-time

Income Statement 47 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`SalesRevenueNet`	$5.07B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$5.65B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.81B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.72B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.35B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.84B	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$317.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$432.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$958.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$771.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$329.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$366.00M	USD	1 Quarter
Other asset Impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$240.00M	USD	1 Quarter
Other asset Impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$707.00M	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$180.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$20.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-1.28B	USD	1 Quarter
Other income	`OtherIncome`	$72.00M	USD	1 Quarter
Other income	`OtherIncome`	$203.00M	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$1.52B	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$895.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-207.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-271.00M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$688.00M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.25B	USD	1 Quarter
Income taxes	`IncomeTaxExpenseBenefit`	$46.00M	USD	1 Quarter
Income taxes	`IncomeTaxExpenseBenefit`	$54.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$7.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-74.00M	USD	1 Quarter
Net income	`ProfitLoss`	$641.00M	USD	1 Quarter
Net income	`ProfitLoss`	$1.13B	USD	1 Quarter
Net Income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$14.00M	USD	1 Quarter
Net Income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-4.00M	USD	1 Quarter
Net income attributable to Teva	`NetIncomeLoss`	$1.12B	USD	1 Quarter
Net income attributable to Teva	`NetIncomeLoss`	$645.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Net income attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$580.00M	USD	1 Quarter
Net income attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$1.05B	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.57	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$1.04	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$1.03	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.57	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfSharesOutstandingDiluted`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfSharesOutstandingDiluted`	1.02B	shares	1 Quarter

Cash Flow Statement 59 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$641.00M	USD	1 Quarter
Net income	`ProfitLoss`	$1.13B	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$592.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$797.00M	USD	1 Quarter
Impairment of long-lived assets	`AssetImpairmentCharges`	$11.00M	USD	1 Quarter
Impairment of long-lived assets	`AssetImpairmentCharges`	$432.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$507.00M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$480.00M	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$180.00M	USD	1 Quarter
Deferred income taxes - net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-221.00M	USD	1 Quarter
Deferred income taxes - net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-217.00M	USD	1 Quarter
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$106.00M	USD	1 Quarter
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$39.00M	USD	1 Quarter
Impairment of equity investment	`ImpairmentOfInvestments`	$94.00M	USD	1 Quarter
Research and development in process	`ResearchAndDevelopmentExpense`	$54.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$40.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$30.00M	USD	1 Quarter
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-17.00M	USD	1 Quarter
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$16.00M	USD	1 Quarter
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$136.00M	USD	1 Quarter
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.50B	USD	1 Quarter
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$824.00M	USD	1 Quarter
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$1.41B	USD	1 Quarter
Beneficial interest collected in exchanged for securitized trade receivables	`CashFlowsBetweenTransferorAndTransfereeBeneficialInterest`	$444.00M	USD	1 Quarter
Beneficial interest collected in exchanged for securitized trade receivables	`CashFlowsBetweenTransferorAndTransfereeBeneficialInterest`	$334.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$202.00M	USD	1 Quarter
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$163.00M	USD	1 Quarter
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$6.00M	USD	1 Quarter
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$56.00M	USD	1 Quarter
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$10.00M	USD	1 Quarter
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$22.00M	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.52B	USD	1 Quarter
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.04B	USD	1 Quarter
Repayment of long-term loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$6.24B	USD	1 Quarter
Proceeds from long-term loans, net of issuance costs	`ProceedsFromIssuanceOfLongTermDebt`	$4.44B	USD	1 Quarter
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-1.35B	USD	1 Quarter
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-261.00M	USD	1 Quarter
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$12.00M	USD	1 Quarter
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$346.00M	USD	1 Quarter
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	$65.00M	USD	1 Quarter
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	$10.00M	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-7.00M	USD	1 Quarter
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-5.00M	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-1.77B	USD	1 Quarter
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.09B	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$28.00M	USD	1 Quarter
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$11.00M	USD	1 Quarter
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-88.00M	USD	1 Quarter
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$455.00M	USD	1 Quarter
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$900.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$1.42B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$900.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$1.42B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$551.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$285.00M	USD	Point-in-time

Comprehensive Income 17 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$641.00M	USD	1 Quarter
Net income	`ProfitLoss`	$1.13B	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$239.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$466.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-8.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$44.00M	USD	1 Quarter
Unrealized gain from available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$54.00M	USD	1 Quarter
Unrealized gain from available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	1 Quarter
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-13.00M	USD	1 Quarter
Total other comprehensive income	`OtherComprehensiveIncomeLossNetOfTax`	$515.00M	USD	1 Quarter
Total other comprehensive income	`OtherComprehensiveIncomeLossNetOfTax`	$196.00M	USD	1 Quarter
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$1.33B	USD	1 Quarter
Total comprehensive income	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$1.16B	USD	1 Quarter
Comprehensive income attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$97.00M	USD	1 Quarter
Comprehensive income attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$66.00M	USD	1 Quarter
Comprehensive income attributable to Teva	`ComprehensiveIncomeNetOfTax`	$1.23B	USD	1 Quarter
Comprehensive income attributable to Teva	`ComprehensiveIncomeNetOfTax`	$1.09B	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.